The First Interoperable Implanted CGM: The Eversense 365 and Twiist Insulin Pump

On February 16, 2026, parent companies Sequel Med Tech and Senseonics announced and launched a combination of the Twiist automated insulin delivery system and the Eversense 365, the first and only 1-year implantable continuous glucose monitor (CGM). This interoperability opens many doors for patients currently using the Eversense 365 for type 1 diabetes (T1D).1

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the announcement and its implications for patients seeking lower-maintenance CGM options.

Check out the full episode on implantable insulin pumps and interoperability here.

In this segment, the hosts turn their attention to the full commercial launch of the Eversense 365 CGM system integrated with the Twiist insulin pump, marking the first officially available pump partnership for the one-year implantable CGM. While an early release phase had already begun, the system is now broadly accessible, representing a meaningful expansion in diabetes technology options. The discussion situates this development within the broader theme of patient-centered device selection, underscoring that no single pump or sensor is optimal for all individuals with diabetes.

A central focus of the conversation is the clinical and experiential value of the Eversense 365 system. Unlike traditional transcutaneous CGMs requiring replacement every 7 to 15 days, the implantable sensor remains in place for up to one year, eliminating the recurring burden of frequent insertions and the variability often associated with “day one” sensor performance. Although initial calibrations are required, ongoing calibration frequency has been reduced to approximately once weekly, which the hosts describe as a manageable tradeoff for many patients. Importantly, after the early calibration phase, users no longer experience routine warm-up periods with each new sensor cycle.

The removable external transmitter is highlighted as a distinguishing feature. Because it sits atop the skin and can be detached temporarily, users can remove it during activities or simply take a break from wearing visible hardware, then reattach it to obtain readings. This flexibility may appeal to patients seeking intermittent device-free intervals without sacrificing long-term sensor continuity.

Accuracy and reliability are also emphasized. The hosts note strong performance metrics and specifically reference the absence of “pressure lows,” a phenomenon observed with some interstitial CGMs when external compression affects glucose readings. For individuals with skin sensitivity, adhesion challenges, or recurrent accuracy concerns related to sensor placement, the implantable system may offer a clinically meaningful alternative.

Finally, Isaacs and Bellini reflect on the broader implications of pump integration. Previously, lthe ack of pump connectivity limited adoption among patients committed to automated insulin delivery systems. With Eversense now communicating directly with a commercial pump, the potential user base may expand. The hosts conclude by expressing interest in whether additional pump manufacturers will pursue similar collaborations, suggesting that this milestone may catalyze greater interoperability and reinforce the importance of individualized, choice-driven diabetes technology strategies.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

References

1. Senseonics. Sequel Med Tech and Senseonics Launch Transformative Combination of twiist and Eversense 365. February 19, 2026. Accessed February 23, 2026. https://www.senseonics.com/investor-relations/news-releases/2026/02-19-2026-130316928